Research programme: ubiquitin modulators - Progenra

Drug Profile

Research programme: ubiquitin modulators - Progenra

Alternative Names: Deubiquitylating enzyme inhibitors - Progenra; MuRF1 inhibitors - Progenra; P 013222; P 022077; P 13222; P 5091; P005091; P1001; P1002; P1003; Synoviolin/Hrd1 inhibitors - Progenra; ubiquitin isopeptidase inhibitors - Progenra; USP2 inhibitors - Progenra; USP47 inhibitors - Progenra; USP7 inhibitors - Progenra

Latest Information Update: 15 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Progenra
  • Class Small molecules
  • Mechanism of Action Endopeptidase inhibitors; Ubiquitin-protein ligase inhibitors; USP2 protein inhibitors; USP47 protein inhibitors; USP7 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Multiple myeloma; Muscular atrophy
  • Research Rheumatoid arthritis

Most Recent Events

  • 10 May 2017 Progenra receives patent allowance for its USP7 inhibitor
  • 10 May 2017 Progenra plans a phase I trial for its USP7 inhibitor for Cancer in 2018
  • 16 Apr 2016 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top